Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic rats
Biopharmaceutics & Drug Disposition · 2013-05 · 34 (4) · 203-214
DOI: 10.1002/bdd.1838 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 07.04.2013. Verfasst von Dong-Yang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Methotrexate (MTX) is an anchor drug used to treat rheumatoid arthritis (RA), but responsiveness is variable in effectiveness and toxicity. Methotrexate and its polyglutamate conjugates (MTXPG n ) in red blood cells (RBC) have been associated with patient response. In the current study, 13 collagen‐induced arthritic (CIA) rats and 12 healthy rats were given subcutaneous doses of either saline or 0.3 or 1.5 mg/kg per 2 days of MTX from day 21 to 43 post‐induction. Blood samples were obtained at various times to measure MTX in plasma, and MTX and MTXPG n in RBC. Effects on disease progression were indicated by body weight and paw size. After multiple‐doses, RBC MTX reached steady‐state (82.4 n m ) within 4 days. The MTXPG 2 and MTXPG 3 in RBC kept increasing until the end of the study, attaining 12.5 and 17.7 n m . Significant weight loss was observed after dosing with 1.5 mg/kg/2 days, whereas moderate effectiveness was observed after dosing with 0.3 mg/kg/2 days. A pharmacokinetic/pharmacodynamic/disease (PK/PD/DIS) model with indirect mechanisms and transduction components incorporating plasma MTX, RBC MTX and RBC MTXPG n concentrations, and paw size was developed using naïve data pooling and ADAPT 5. The PK/PD in CIA rats dosed at 0.3 mg/kg/2 days were captured well by our proposed model. Methotrexate showed modest ( I maxd = 0.16) but sensitive ( IC 50d = 0.712 n m ) effectiveness on paw edema. The higher dose produced toxicity. The proposed model offers improved understanding of the effects of methotrexate on rheumatoid arthritis. Copyright © 2013 John Wiley & Sons, Ltd.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Liu, D. Y., Lon, H. K., Wang, Y. L., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2013). Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic rats. Biopharmaceutics & Drug Disposition, 34(4), 203-214. https://doi.org/10.1002/bdd.1838
Vancouver
Liu DY, Lon HK, Wang YL, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic rats. Biopharmaceutics & Drug Disposition. 2013;34(4):203-214. doi:10.1002/bdd.1838
BibTeX
@article{Liu2013,
author = {Liu, Dong-Yang and Lon, Hoi-Kei and Wang, Yan-Lin and DuBois, Debra C and Almon, Richard R and Jusko, William J},
title = {Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic rats},
journal = {Biopharmaceutics & Drug Disposition},
year = {2013},
volume = {34},
number = {4},
pages = {203--214},
doi = {10.1002/bdd.1838}
}
EUVIMED